Country Club Bank Acquires Shares of 134,437 Elanco Animal Health Incorporated (NYSE:ELAN)

Country Club Bank acquired a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 134,437 shares of the company’s stock, valued at approximately $1,925,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Hunter Associates Investment Management LLC increased its stake in shares of Elanco Animal Health by 5.1% in the first quarter. Hunter Associates Investment Management LLC now owns 16,600 shares of the company’s stock valued at $269,000 after buying an additional 800 shares in the last quarter. 180 Wealth Advisors LLC increased its stake in shares of Elanco Animal Health by 3.6% in the second quarter. 180 Wealth Advisors LLC now owns 25,716 shares of the company’s stock valued at $352,000 after buying an additional 893 shares in the last quarter. HBK Sorce Advisory LLC increased its stake in shares of Elanco Animal Health by 9.4% in the second quarter. HBK Sorce Advisory LLC now owns 12,920 shares of the company’s stock valued at $186,000 after buying an additional 1,107 shares in the last quarter. Atomi Financial Group Inc. increased its stake in shares of Elanco Animal Health by 11.1% in the second quarter. Atomi Financial Group Inc. now owns 12,260 shares of the company’s stock valued at $177,000 after buying an additional 1,221 shares in the last quarter. Finally, Keene & Associates Inc. increased its stake in shares of Elanco Animal Health by 5.7% in the third quarter. Keene & Associates Inc. now owns 22,945 shares of the company’s stock valued at $337,000 after buying an additional 1,240 shares in the last quarter. 97.48% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

ELAN has been the subject of a number of research reports. Stifel Nicolaus reiterated a “buy” rating and issued a $20.00 price objective on shares of Elanco Animal Health in a research report on Thursday, September 19th. Piper Sandler lowered their price objective on Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating for the company in a research report on Monday, July 1st. Morgan Stanley lowered Elanco Animal Health from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $17.00 to $15.00 in a research report on Thursday, September 19th. Finally, Barclays lifted their price objective on Elanco Animal Health from $21.00 to $22.00 and gave the stock an “overweight” rating in a research report on Monday, September 23rd. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $17.43.

Elanco Animal Health Price Performance

Elanco Animal Health stock opened at $12.41 on Friday. The firm has a market capitalization of $6.13 billion, a P/E ratio of -4.87, a PEG ratio of 1.32 and a beta of 1.40. Elanco Animal Health Incorporated has a 1 year low of $8.52 and a 1 year high of $18.80. The business has a 50-day moving average of $14.32 and a 200-day moving average of $14.79. The company has a current ratio of 2.93, a quick ratio of 1.75 and a debt-to-equity ratio of 0.92.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Thursday, August 8th. The company reported $0.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.06. Elanco Animal Health had a positive return on equity of 7.29% and a negative net margin of 27.94%. The company had revenue of $1.18 billion during the quarter, compared to analyst estimates of $1.15 billion. During the same period in the previous year, the company earned $0.18 EPS. The company’s revenue for the quarter was up 12.0% compared to the same quarter last year. On average, equities analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Insider Activity

In other Elanco Animal Health news, Director Michael J. Harrington acquired 3,500 shares of the business’s stock in a transaction dated Thursday, August 22nd. The shares were acquired at an average price of $14.85 per share, for a total transaction of $51,975.00. Following the acquisition, the director now directly owns 81,094 shares of the company’s stock, valued at approximately $1,204,245.90. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, CEO Jeffrey N. Simmons bought 100,000 shares of the business’s stock in a transaction on Monday, August 12th. The shares were purchased at an average price of $13.01 per share, for a total transaction of $1,301,000.00. Following the purchase, the chief executive officer now owns 145,000 shares of the company’s stock, valued at approximately $1,886,450. The trade was a 200.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Michael J. Harrington bought 3,500 shares of the business’s stock in a transaction on Thursday, August 22nd. The stock was purchased at an average price of $14.85 per share, for a total transaction of $51,975.00. Following the purchase, the director now directly owns 81,094 shares in the company, valued at approximately $1,204,245.90. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. 0.57% of the stock is currently owned by company insiders.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.